SuperworthCrescent Biopharma EPS CBIO
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Dec 31, 2024
- −$46.00
- Latest quarter, Q4 FY24
- −$11.00
- Fiscal year 2024
- −$46.00
Crescent Biopharma's earnings per share was −$46.00 over the twelve months to Dec 31, 2024.
In its latest quarter, Q4 FY24, it was −$11.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$46.00 | n/a |
| FY2023 | −$58.00 | n/a |
| FY2022 | −$88.00 | n/a |
| FY2021 | −$123.00 | n/a |
| FY2020 | −$111.00 | n/a |
| FY2019 | −$135.00 | n/a |
| FY2018 | −$112.00 | n/a |
| FY2017 | −$115.00 | n/a |
| FY2016 | −$151.00 | n/a |
| FY2015 | −$71.00 | n/a |
| FY2014 | −$65.00 | n/a |
| FY2013 | −$898.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY24 | −$11.00 | n/a | −$46.00 | |
| Q3 FY24 | −$15.00 | n/a | −$49.00 | |
| Q2 FY24 | −$16.00 | n/a | −$48.00 | |
| Q1 FY24 | −$4.00 | n/a | −$45.00 | |
| Q4 FY23 | −$14.00 | n/a | −$58.00 | |
| Q3 FY23 | −$14.00 | n/a | −$63.00 | |
| Q2 FY23 | −$13.00 | n/a | −$65.00 | |
| Q1 FY23 | −$17.00 | n/a | −$77.00 | |
| Q4 FY22 | −$19.00 | n/a | −$88.00 | |
| Q3 FY22 | −$16.00 | n/a | −$102.00 | |
| Q2 FY22 | −$25.00 | n/a | −$120.00 | |
| Q1 FY22 | −$28.00 | n/a | −$123.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Crescent Biopharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CBIOCrescent Biopharma | n/m | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Crescent Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.